

Freedom of Information Request	FOI 22-389	2 nd September 2022
--------------------------------	------------	--------------------------------

Q1. In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

The Health Board has not issued any of these products over the past 3-months.

Q2. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

No severe haemophilia A patients have required treatment with the Health Board for this period. Haemophilia A patients are all managed by [Cardiff & Vale University Health Board](#) therefore you may wish to contact them direct for this information.